

Immunologic Treatment of intraocular melanoma after enucleation to avoid metastatic melanoma

ESVO Meeting October 3 - 6 2019 Dun Laoghaire, Dublin, Ireland

Authors: Dr. Kirsten Penner | Tierarztpraxis Ferdinand Nießen, Düsseldorf, Germany | info@tierdoc.org Dr. Tina Hawacker | Tiergesundheitszentrum Suedharz GmbH, Osterode am Harz, Germany | t.hawacker@tgz-suedharz.de Dr. Thomas Grammel | Tiergesundheitszentrum Suedharz GmbH, Osterode am Harz, Germany | tgrammel@dr-grammel.de

Purpose

Two dogs underwent an enucleation because of a malign process in the posterior section of the eye. The pathologist reported no clean margins in the histological sections. To avoid metastatic disease the dendritic cell therapy was started soon after the surgery.

Material/method

1ml whole blood per kg of body weight was taken from the dogs. Following a centrifugation and adherence phase a monocyte fraction was obtained. These monocytes were cultivated in a cleanroom environment with canine cytokines (GM-CSF and IL-4) to derive autologous DCs. The treatment was carried out three times in a monthly interval after renewed blood sampling and cell preparation of the monocytes. The treatment was administered at three anatomical sites: locally in the area of the surgical field, intradermal in the area of the mandibular lymph nodes and the axillary lymph nodes.

Results

The dogs live more than two years after enucleation without any sign of recurrence or metastasis of the melanoma.

Discussion

Immunological treatment with dendritic cells derived from monocytes can prevent recurrence/ metastasis of ocular melanoma. Therefore, such a therapy should be considered for malignant eye diseases after enucleation.

Procedure Dog 1

Crossbreed, female, 15 years, 5.6 kg


| Date | Milestone | Day |
|----------|-----------------|-----|
| 06.09.17 | Surgery | 0 |
| 26.09.17 | 1st Application | 20 |
| 25.10.17 | 2nd Application | 49 |
| 17.11.17 | 3rd Application | 72 |
| 28.08.19 | Follow-up | 721 |

Recommended initial treatment

Procedure Dog 2

Crossbreed, female, 9 years, 15 kg

| Date | Milestone | Day |
|----------|------------------|------|
| 16.02.16 | Surgery | 0 |
| 07.04.16 | 1st Application | 51 |
| 26.04.16 | 2nd Application | 70 |
| 01.09.16 | 3rd Application | 198 |
| 27.10.16 | 4th Application | 254 |
| 04.05.17 | 5th Application | 443 |
| 01.09.17 | 6th Application | 563 |
| 01.02.18 | 7th Application | 716 |
| 12.07.18 | 8th Application | 877 |
| 17.01.19 | 9th Application | 1066 |
| 02.08.19 | 10th Application | 1263 |
| 28.08.19 | Follow-up | 1289 |



Dog 1 before surgery



Dog 2 before surgery



Dog 2 after surgery

Recommended treatment procedure

| I | Day 0 | | 1 | | |
|---|-------|--------------------------|--------------------------|--------------------------|-------------------------------|
| | | Day 7 | | | |
| | | 1st Application with DCs | Day 35 | | |
| | | | 2nd Application with DCs | Day 86 | |
| | | | | 3rd Application with DCs | Every 150 days |
| | | | | | Follow-up treatments with DCs |

Literature

Dubielzig R. (2014). Tumors of the Canine Globe. Presentation, School of Vet Med U Wisc

Grammel T. (2014). Canine Melanoma Treated with Autologous Dendritic Cell-Based Vaccines in 10 dogs. Presentation, ESVONC Congress, Vienna, Austria Hyman JA, Koch SA, Wilcock BP (2002). Canine choroidal melanoma with metastases

Miller PE and Dubielzig PE (2013): Ocular Tumors in: Withrow & MacEwen's Small Animal Clinical Oncology, 597-601, Saunders, St. Louis, MI

Westermeyer D, Hendrix DV (2012). Surgical Procedures for Globe Removal in: Tobias KM, Johnston SA, Veterinary Surgery Small Animal, 2117-2119, Elsevier, St. Louis, MI

Yi N-Y, Park S-A, Park S-W, Jeong M-B, Kang M-S, Jung J-H, Choi M-C, Kim D-Y, Nam T-C, Seo K-M (2006), Malignant ocular melanoma in a dog. J Vet Sci. 7(1): 89–90.